User login
THE PRESENTATION
A Early central centrifugal cicatricial alopecia with a small central patch of hair loss in a 45-year-old Black woman.
B Late central centrifugal cicatricial alopecia with a large central patch of hair loss in a 43-year-old Black woman.
Scarring alopecia is a collection of hair loss disorders including chronic cutaneous lupus erythematosus (discoid lupus), lichen planopilaris, dissecting cellulitis, acne keloidalis, and central centrifugal cicatricial alopecia.1 CCCA (formerly hot comb alopecia or follicular degeneration syndrome) is a progressive, scarring, inflammatory alopecia and represents the most common form of scarring alopecia in women of African descent. It results in permanent destruction of hair follicles.
Epidemiology
CCCA predominantly affects women of African descent but also may affect men. The prevalence of CCCA in those of African descent has varied in the literature. Khumalo2 reported a prevalence of 1.2% for women younger than 50 years and 6.7% in women older than 50 years. CCCA has been reported in other ethnic groups, such as those of Asian descent.3
Historically, hair care practices that are more common in those of African descent, such as high-tension hairstyles as well as heat and chemical hair relaxers, were implicated in the development of CCCA. However, the causes of CCCA are most likely multifactorial, including family history, genetic mutations, and hair care practices.4-7PADI3 mutations likely predispose some women to CCCA. Mutations in PADI3, which encodes peptidyl arginine deiminase 3 (an enzyme that modifies proteins crucial for the formation of hair shafts), were found in some patients with CCCA.8 Moreover, other genetic defects also likely play a role.7
Key clinical features
Early recognition is key for patients with CCCA.
- CCCA begins in the central scalp (crown area, vertex) and spreads centrifugally.
- Scalp symptoms such as tenderness, pain, a tingling or crawling sensation, and itching may occur.9 Some patients may not have any symptoms at all, and hair loss may progress painlessly.
- Central hair breakage—forme fruste CCCA—may be a presenting sign of CCCA.9
- Loss of follicular ostia and mottled hypopigmented and hyperpigmented macules are common findings.6
- CCCA can be diagnosed clinically and by histopathology.
Worth noting
Patients may experience hair loss and scalp symptoms for years before seeking medical evaluation. In some cultures, hair breakage or itching on the top of the scalp may be viewed as a normal occurrence in life.
It is important to set patient expectations that CCCA is a scarring alopecia, and the initial goal often is to maintain the patient's existing hair. However, hair and areas responding to treatment should still be treated. Without any intervention, the resulting scarring from CCCA may permanently scar follicles on the entire scalp.
Continue to: Due to the inflammatory...
Due to the inflammatory nature of CCCA, potent topical corticosteroids (eg, clobetasol propionate), intralesional corticosteroids (eg, triamcinolone acetonide), and oral antiinflammatory agents (eg, doxycycline) are utilized in the treatment of CCCA. Minoxidil is another treatment option. Adjuvant therapies such as topical metformin also have been tried.10 Importantly, treatment of CCCA may halt further permanent destruction of hair follicles, but scalp symptoms may reappear periodically and require re-treatment with anti-inflammatory agents.
Health care highlight
Thorough scalp examination and awareness of clinical features of CCCA may prompt earlier diagnosis and prevent future severe permanent alopecia. Clinicians should encourage patients with suggestive signs or symptoms of CCCA to seek care from a dermatologist.
1. Sperling LC. Scarring alopecia and the dermatopathologist. J Cutan Pathol. 2001;28:333-342. doi:10.1034/ j.1600-0560.2001.280701.x
2. Khumalo NP. Prevalence of central centrifugal cicatricial alopecia. Arch Dermatol. 2011;147:1453-1454. doi:10.1001/ archderm.147.12.1453
3. Su HJ, Cheng AY, Liu CH, et al. Primary scarring alopecia: a retrospective study of 89 patients in Taiwan [published online January 16, 2018]. J Dermatol. 2018;45:450-455. doi:10.1111/ 1346-8138.14217
4. Sperling LC, Cowper SE. The histopathology of primary cicatricial alopecia. Semin Cutan Med Surg. 2006;25:41-50
5. Dlova NC, Forder M. Central centrifugal cicatricial alopecia: possible familial aetiology in two African families from South Africa. Int J Dermatol. 2012;51(supp 1):17-20, 20-23.
6. Ogunleye TA, Quinn CR, McMichael A. Alopecia. In: Taylor SC, Kelly AP, Lim HW, et al, eds. Dermatology for Skin of Color. McGraw Hill; 2016:253-264.
7. Uitto J. Genetic susceptibility to alopecia [published online February 13, 2019]. N Engl J Med. 2019;380:873-876. doi:10.1056/ NEJMe1900042
8. Malki L, Sarig O, Romano MT, et al. Variant PADI3 in central centrifugal cicatricial alopecia. N Engl J Med. 2019;380:833-841.
9. Callender VD, Wright DR, Davis EC, et al. Hair breakage as a presenting sign of early or occult central centrifugal cicatricial alopecia: clinicopathologic findings in 9 patients. Arch Dermatol. 2012;148:1047-1052.
10. Araoye EF, Thomas JAL, Aguh CU. Hair regrowth in 2 patients with recalcitrant central centrifugal cicatricial alopecia after use of topical metformin. JAAD Case Rep. 2020;6:106-108. doi:10.1016/ j.jdcr.2019.12.008.
THE PRESENTATION
A Early central centrifugal cicatricial alopecia with a small central patch of hair loss in a 45-year-old Black woman.
B Late central centrifugal cicatricial alopecia with a large central patch of hair loss in a 43-year-old Black woman.
Scarring alopecia is a collection of hair loss disorders including chronic cutaneous lupus erythematosus (discoid lupus), lichen planopilaris, dissecting cellulitis, acne keloidalis, and central centrifugal cicatricial alopecia.1 CCCA (formerly hot comb alopecia or follicular degeneration syndrome) is a progressive, scarring, inflammatory alopecia and represents the most common form of scarring alopecia in women of African descent. It results in permanent destruction of hair follicles.
Epidemiology
CCCA predominantly affects women of African descent but also may affect men. The prevalence of CCCA in those of African descent has varied in the literature. Khumalo2 reported a prevalence of 1.2% for women younger than 50 years and 6.7% in women older than 50 years. CCCA has been reported in other ethnic groups, such as those of Asian descent.3
Historically, hair care practices that are more common in those of African descent, such as high-tension hairstyles as well as heat and chemical hair relaxers, were implicated in the development of CCCA. However, the causes of CCCA are most likely multifactorial, including family history, genetic mutations, and hair care practices.4-7PADI3 mutations likely predispose some women to CCCA. Mutations in PADI3, which encodes peptidyl arginine deiminase 3 (an enzyme that modifies proteins crucial for the formation of hair shafts), were found in some patients with CCCA.8 Moreover, other genetic defects also likely play a role.7
Key clinical features
Early recognition is key for patients with CCCA.
- CCCA begins in the central scalp (crown area, vertex) and spreads centrifugally.
- Scalp symptoms such as tenderness, pain, a tingling or crawling sensation, and itching may occur.9 Some patients may not have any symptoms at all, and hair loss may progress painlessly.
- Central hair breakage—forme fruste CCCA—may be a presenting sign of CCCA.9
- Loss of follicular ostia and mottled hypopigmented and hyperpigmented macules are common findings.6
- CCCA can be diagnosed clinically and by histopathology.
Worth noting
Patients may experience hair loss and scalp symptoms for years before seeking medical evaluation. In some cultures, hair breakage or itching on the top of the scalp may be viewed as a normal occurrence in life.
It is important to set patient expectations that CCCA is a scarring alopecia, and the initial goal often is to maintain the patient's existing hair. However, hair and areas responding to treatment should still be treated. Without any intervention, the resulting scarring from CCCA may permanently scar follicles on the entire scalp.
Continue to: Due to the inflammatory...
Due to the inflammatory nature of CCCA, potent topical corticosteroids (eg, clobetasol propionate), intralesional corticosteroids (eg, triamcinolone acetonide), and oral antiinflammatory agents (eg, doxycycline) are utilized in the treatment of CCCA. Minoxidil is another treatment option. Adjuvant therapies such as topical metformin also have been tried.10 Importantly, treatment of CCCA may halt further permanent destruction of hair follicles, but scalp symptoms may reappear periodically and require re-treatment with anti-inflammatory agents.
Health care highlight
Thorough scalp examination and awareness of clinical features of CCCA may prompt earlier diagnosis and prevent future severe permanent alopecia. Clinicians should encourage patients with suggestive signs or symptoms of CCCA to seek care from a dermatologist.
THE PRESENTATION
A Early central centrifugal cicatricial alopecia with a small central patch of hair loss in a 45-year-old Black woman.
B Late central centrifugal cicatricial alopecia with a large central patch of hair loss in a 43-year-old Black woman.
Scarring alopecia is a collection of hair loss disorders including chronic cutaneous lupus erythematosus (discoid lupus), lichen planopilaris, dissecting cellulitis, acne keloidalis, and central centrifugal cicatricial alopecia.1 CCCA (formerly hot comb alopecia or follicular degeneration syndrome) is a progressive, scarring, inflammatory alopecia and represents the most common form of scarring alopecia in women of African descent. It results in permanent destruction of hair follicles.
Epidemiology
CCCA predominantly affects women of African descent but also may affect men. The prevalence of CCCA in those of African descent has varied in the literature. Khumalo2 reported a prevalence of 1.2% for women younger than 50 years and 6.7% in women older than 50 years. CCCA has been reported in other ethnic groups, such as those of Asian descent.3
Historically, hair care practices that are more common in those of African descent, such as high-tension hairstyles as well as heat and chemical hair relaxers, were implicated in the development of CCCA. However, the causes of CCCA are most likely multifactorial, including family history, genetic mutations, and hair care practices.4-7PADI3 mutations likely predispose some women to CCCA. Mutations in PADI3, which encodes peptidyl arginine deiminase 3 (an enzyme that modifies proteins crucial for the formation of hair shafts), were found in some patients with CCCA.8 Moreover, other genetic defects also likely play a role.7
Key clinical features
Early recognition is key for patients with CCCA.
- CCCA begins in the central scalp (crown area, vertex) and spreads centrifugally.
- Scalp symptoms such as tenderness, pain, a tingling or crawling sensation, and itching may occur.9 Some patients may not have any symptoms at all, and hair loss may progress painlessly.
- Central hair breakage—forme fruste CCCA—may be a presenting sign of CCCA.9
- Loss of follicular ostia and mottled hypopigmented and hyperpigmented macules are common findings.6
- CCCA can be diagnosed clinically and by histopathology.
Worth noting
Patients may experience hair loss and scalp symptoms for years before seeking medical evaluation. In some cultures, hair breakage or itching on the top of the scalp may be viewed as a normal occurrence in life.
It is important to set patient expectations that CCCA is a scarring alopecia, and the initial goal often is to maintain the patient's existing hair. However, hair and areas responding to treatment should still be treated. Without any intervention, the resulting scarring from CCCA may permanently scar follicles on the entire scalp.
Continue to: Due to the inflammatory...
Due to the inflammatory nature of CCCA, potent topical corticosteroids (eg, clobetasol propionate), intralesional corticosteroids (eg, triamcinolone acetonide), and oral antiinflammatory agents (eg, doxycycline) are utilized in the treatment of CCCA. Minoxidil is another treatment option. Adjuvant therapies such as topical metformin also have been tried.10 Importantly, treatment of CCCA may halt further permanent destruction of hair follicles, but scalp symptoms may reappear periodically and require re-treatment with anti-inflammatory agents.
Health care highlight
Thorough scalp examination and awareness of clinical features of CCCA may prompt earlier diagnosis and prevent future severe permanent alopecia. Clinicians should encourage patients with suggestive signs or symptoms of CCCA to seek care from a dermatologist.
1. Sperling LC. Scarring alopecia and the dermatopathologist. J Cutan Pathol. 2001;28:333-342. doi:10.1034/ j.1600-0560.2001.280701.x
2. Khumalo NP. Prevalence of central centrifugal cicatricial alopecia. Arch Dermatol. 2011;147:1453-1454. doi:10.1001/ archderm.147.12.1453
3. Su HJ, Cheng AY, Liu CH, et al. Primary scarring alopecia: a retrospective study of 89 patients in Taiwan [published online January 16, 2018]. J Dermatol. 2018;45:450-455. doi:10.1111/ 1346-8138.14217
4. Sperling LC, Cowper SE. The histopathology of primary cicatricial alopecia. Semin Cutan Med Surg. 2006;25:41-50
5. Dlova NC, Forder M. Central centrifugal cicatricial alopecia: possible familial aetiology in two African families from South Africa. Int J Dermatol. 2012;51(supp 1):17-20, 20-23.
6. Ogunleye TA, Quinn CR, McMichael A. Alopecia. In: Taylor SC, Kelly AP, Lim HW, et al, eds. Dermatology for Skin of Color. McGraw Hill; 2016:253-264.
7. Uitto J. Genetic susceptibility to alopecia [published online February 13, 2019]. N Engl J Med. 2019;380:873-876. doi:10.1056/ NEJMe1900042
8. Malki L, Sarig O, Romano MT, et al. Variant PADI3 in central centrifugal cicatricial alopecia. N Engl J Med. 2019;380:833-841.
9. Callender VD, Wright DR, Davis EC, et al. Hair breakage as a presenting sign of early or occult central centrifugal cicatricial alopecia: clinicopathologic findings in 9 patients. Arch Dermatol. 2012;148:1047-1052.
10. Araoye EF, Thomas JAL, Aguh CU. Hair regrowth in 2 patients with recalcitrant central centrifugal cicatricial alopecia after use of topical metformin. JAAD Case Rep. 2020;6:106-108. doi:10.1016/ j.jdcr.2019.12.008.
1. Sperling LC. Scarring alopecia and the dermatopathologist. J Cutan Pathol. 2001;28:333-342. doi:10.1034/ j.1600-0560.2001.280701.x
2. Khumalo NP. Prevalence of central centrifugal cicatricial alopecia. Arch Dermatol. 2011;147:1453-1454. doi:10.1001/ archderm.147.12.1453
3. Su HJ, Cheng AY, Liu CH, et al. Primary scarring alopecia: a retrospective study of 89 patients in Taiwan [published online January 16, 2018]. J Dermatol. 2018;45:450-455. doi:10.1111/ 1346-8138.14217
4. Sperling LC, Cowper SE. The histopathology of primary cicatricial alopecia. Semin Cutan Med Surg. 2006;25:41-50
5. Dlova NC, Forder M. Central centrifugal cicatricial alopecia: possible familial aetiology in two African families from South Africa. Int J Dermatol. 2012;51(supp 1):17-20, 20-23.
6. Ogunleye TA, Quinn CR, McMichael A. Alopecia. In: Taylor SC, Kelly AP, Lim HW, et al, eds. Dermatology for Skin of Color. McGraw Hill; 2016:253-264.
7. Uitto J. Genetic susceptibility to alopecia [published online February 13, 2019]. N Engl J Med. 2019;380:873-876. doi:10.1056/ NEJMe1900042
8. Malki L, Sarig O, Romano MT, et al. Variant PADI3 in central centrifugal cicatricial alopecia. N Engl J Med. 2019;380:833-841.
9. Callender VD, Wright DR, Davis EC, et al. Hair breakage as a presenting sign of early or occult central centrifugal cicatricial alopecia: clinicopathologic findings in 9 patients. Arch Dermatol. 2012;148:1047-1052.
10. Araoye EF, Thomas JAL, Aguh CU. Hair regrowth in 2 patients with recalcitrant central centrifugal cicatricial alopecia after use of topical metformin. JAAD Case Rep. 2020;6:106-108. doi:10.1016/ j.jdcr.2019.12.008.
